Skip to main content

Table 2 Evaluation of blood stream infections.

From: Taurolidine-citrate lock solution (TauroLock) significantly reduces CVAD-associated grampositive infections in pediatric cancer patients

Item Group 1
(heparin)
Group 2
(TauroLock™)
P value
No. of BSI events 30 25  
No. (%) of patients with at least 1 BSI 24 (27) 21 (24) 0.74
No. (%) of BSI with CoNS* or MRSE§ 14 (47) 3 (11) 0.004
     CoNS: 4 (13)    CoNS: 3 (11)  
     MRSE: 10 (33)    MRSE: 0 (0)  
Incidence density for All BSI events (CI95) 4.93 (3.33–7.04) 3.82 (2.52–5.56) 0.35
Incidence density calculated with the number of specific isolates    
   BSI with CoNS/MRSE 2.30 (1.26–3.86) 0.45 (0.09–1.31) 0.004
   BSI other Gram positive 0.66 (0.18–1.68) 1.19 (0.52–2.35) 0.32
   BSI E. coli 0.66 (0.18–1.68) 1.49 (0.72–2.74) 0.15
   BSI all Gram negative 1,97 (1.02–3.44) 2.24 (1.25–3.69) 0.74
  1. Group 1 = heparin (2004–2005) vs. group 2 = TauroLock™ (2005–2006)
  2. * CoNS = coagulase-negative Staphylococci (methicillin-sensitive)
  3. §MRSE = methicillin-resistant coagulase-negative Staphylococci
  4. + The percentage refers to all documented BSI in this group (100%).
  5. ‡ The ID refers to the number of events per 1000 inpatient CVAD utilization days.
  6. Δ IQR = interquartile range, 25–75. Percentile